Pseudoxanthoma elasticum
| Pseudoxanthoma elasticum | |
| ICD-10 | Q82.8 (ILDS Q82.81) |
|---|---|
| ICD-9 | 757.39 |
| OMIM | 264800 |
| DiseasesDB | 10876 Template:DiseasesDB2 Template:DiseasesDB2 Template:DiseasesDB2 |
| eMedicine | derm/359 oph/475 |
| MeSH | D011561 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pseudoxanthoma elasticum (PXE) is a genetic disease that is caused by autosomal recessive mutations in the ABCC6 gene on the short arm of chromosome 16 (16p13.1). PXE causes fragmentation and mineralization of elastic fibers in some tissues. The most common problems arise in the skin and eyes, and later in blood vessels in the form of premature atherosclerosis.[1]
Diagnosis
Usually, pseudoxanthoma elasticum affects the skin first, often in childhood but frequently later. Small, yellowish papular lesions form and cutaneous laxity mainly affects the neck, axillae (armpits), groin, and flexural creases (the inside parts of the elbows and knees). Skin may become lax and redundant. Many individuals have "oblique mental creases" (diagonal grooves of the chin).[1]
PXE first affects the retina through a dimpling of the Bruch membrane (a thin membrane separating the blood vessel-rich layer from the pigmented layer of the retina), that is only visible during ophthalmologic examinations. This is called peau d'orange (a French term meaning that the retina resembles the skin of an orange). Eventually the mineralization of the elastic fibers in the Bruch membrane create cracks (angioid streaks) that radiate out from the optic nerve. Angioid streaks themselves do not cause distortion of vision, even if they cross into the foveal area. This symptom is present almost all PXE patients and is usually noticed a few years after the onset of cutaneous lesions. These cracks may allow small blood vessels that were originally held back by Bruch's membrane to penetrate the retina. These blood vessels sometimes leak, and it's these retinal hemorrhages that may lead to the loss of central vision. Vision loss is a major issue in many PXE patients.[1]
PXE may affect the gastrointestinal and cardiovascular systems. In the digestive tract, the principal symptom is gastrointestinal bleeding, usually from the stomach. This occurs in very small number of patients. In the circulatory system, intermittent claudication (leg pain during walking which resolves at rest) is a prominent feature, although at later stages coronary artery disease and myocardial infarction may occur.[1]
Classification
The diagnostic criteria for PXE are the typical skin biopsy appearance and the presence of angioid streaks in the retina. Other systems have become somewhat outdated by the discovery of the ABCC6 mutations.[1]
Genetics
80% of clinical cases of pseudoxanthoma elasticum have detectable mutations in the ABCC6 gene.[2][3][4][5] Mutations in almost all parts of the gene have been described, of all types (missense, nonsense, splice alteration, insertion, small deletion or large deletion). Although there have been reports of autosomal dominant inheritance, the inheritance is typically autosomal recessive (both parents need to be carriers, and there is a 25% chance that a child will inherit both abnormal copies of the gene and therefore develop the condition).[1]
Pathophysiology
In PXE, the calcification (accumulation of calcium) and fragmentation of the elastin-containing fibers in connective tissue, but primarily in the midsized arteries.[6]
Strong genetic linkage was found with mutations in the ABCC6 gene, but the exact mechanism by which this protein (which is a membrane transporter from the large ATP-binding cassette transporter family) influences the disease course is unknown; the protein is expressed in most organs, but mainly in the liver and kidney. It is unclear in what way this would lead to abnormalities in skin, eyes and blood vessels. It is thought that particular mutations do not cause a more severe or less severe form of the disease. Given the variations in age of onset and severity it is likely that other unknown risk factors (genetic and dietary) may be involved.[1] Premature atherosclerosis is also associated with mutations in the ABCC6 gene, even in those without PXE.[7]
A syndrome almost indistinguishable from hereditary PXE has been described in patients with hemoglobinopathies (sickle-cell disease and thalassemia) through a poorly understood mechanism.[1]
Treatment
There is no treatment that directly interferes with the disease process, although dietary restriction of calcium has been tried with limited results. For excessive areas of skin, plastic surgery may be needed. For the growth of abnormal blood vessels in the retina, laser eye surgery may be needed in forms similar to that used in diabetic retinopathy (eye damage due to diabetes). Cardiovascular disease is treated as in individuals without PXE. Some recommend avoidance of medication that would increase bleeding risk, such as aspirin.[1]
Epidemiology
The reported prevalence of pseudoxanthoma elasticum is about 1:25,000. Females are twice as likely to be affected as males. The disease occurs in all ethnicities, but South Africans are more likely to have PXE as a result of a founder effect (i.e. it was relatively prevalent in the small group of people from whom most South Africans descend).[1]
History
The first description of PXE that distinguished it from other xanthomatous conditions was by Dr Ferdinand-Jean Darrier in 1896.[8] The eponym "Grönblad-Strandberg syndrome" is used in older literature, after two physicians who made further discoveries in the disease manifestations.[9]
PXE has the distinction of being the only disease for which a layperson is the inventor of the gene, ABCC6. Sharon F. Terry, co-founder of PXE International with her husband, Patrick F. Terry, worked with scientists to discover and patent the gene in 2000.[4] The Terrys' two children have pseudoxanthoma elasticum.[10]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 Chassaing N, Martin L, Calvas P, Le Bert M, Hovnanian A (2005). "Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations". J. Med. Genet. 42 (12): 881–92. doi:10.1136/jmg.2004.030171. PMID 15894595.
- ↑ Ringpfeil F, Lebwohl MG, Christiano AM, Uitto J (2000). "Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter". Proc. Natl. Acad. Sci. U.S.A. 97 (11): 6001–6. doi:10.1073/pnas.100041297. PMID 10811882.
- ↑ Bergen AA, Plomp AS, Schuurman EJ; et al. (2000). "Mutations in ABCC6 cause pseudoxanthoma elasticum". Nat. Genet. 25 (2): 228–31. doi:10.1038/76109. PMID 10835643.
- ↑ 4.0 4.1 Le Saux O, Urban Z, Tschuch C; et al. (2000). "Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum". Nat. Genet. 25 (2): 223–7. doi:10.1038/76102. PMID 10835642.
- ↑ Struk B, Cai L, Zäch S; et al. (2000). "Mutations of the gene encoding the transmembrane transporter protein ABC-C6 cause pseudoxanthoma elasticum". J. Mol. Med. 78 (5): 282–6. PMID 10954200.
- ↑ Gheduzzi D, Sammarco R, Quaglino D, Bercovitch L, Terry S, Taylor W, Ronchetti I (2003). "Extracutaneous ultrastructural alterations in pseudoxanthoma elasticum". Ultrastructural pathology. 27 (6): 375–84. PMID 14660276.
- ↑ Trip MD, Smulders YM, Wegman JJ; et al. (2002). "Frequent mutation in the ABCC6 gene (R1141X) is associated with a strong increase in the prevalence of coronary artery disease". Circulation. 106 (7): 773–5. PMID 12176944.
- ↑ Darier FJ (1896). Pseudoxanthoma elasticum. Monatschr Prakt Dermatol 23:609-17.
- ↑ Template:WhoNamedIt
- ↑ Terry SF, Terry PF, Rauen KA, Uitto J, Bercovitch LG (2007). "Advocacy groups as research organizations: the PXE International example". Nat. Rev. Genet. 8 (2): 157–64. doi:10.1038/nrg1991. PMID 17230202.
External links
- PXE International
- pxe at NIH/UW GeneTests
- Pseudoxanthoma elasticum at NLM Genetics Home Reference